Global Neurotrophic Keratitis Market TOC
Neurotrophic Keratitis Market size is estimated to reach USD 1.45 Billion by the end of 2036, growing at a CAGR of 17.07% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of neurotrophic keratitis was USD 192.54 Million. As one age, the prevalence rate of neurotrophic keratitis rises, which is attributed to boosting the market’s growth. The World Health Organization predicts that by 2030, one in six persons will be 60 years of age or older. By this time, there will be 1.4 billion people in the world who are 60 years of age or older, up from 1 billion in 2020. The number of individuals in the globe who are 60 years of age or older will have doubled to 2.1 billion by 2050. The population of those 80 years of age and older is predicted to treble, to 426 million, between 2020 and 2050.
In addition to these, as the first medication to treat neurotrophic keratitis, a rare corneal illness, the FDA has approved Oxervate. In clinical trials, compared to 28/5 without cenegermin, 70% of patients treated with oxycontin had full corneal healing in eight weeks. Ocular hypermia, eye inflammation, eye discomfort, and increased lacrimation are typical adverse effects. Oxervate was designated as an Orphan Drug and a Priority Review drug, respectively, indicating that it could help treat a rare disease and make a major improvement. The approval for Dompe Farmaceutici SpA was given. This highlights the industry's dedication to meeting unmet medical needs by offering incentives for the development of medications aimed at uncommon diseases.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
17.07% |
|
Base Year Market Size (2023) |
USD 192.54 Million |
|
Forecast Year Market Size (2036) |
USD 1.45 Billion |
|
Regional Scope |
|
Treatment Type (Surgical Intervention, Drugs)
The drugs segment in the neurotrophic keratitis market is the largest and is expected to reach USD 1.06 billion by 2036, rising at a substantial CAGR of 17.19% between 2024 and 2036. In 2023, the segment was worth USD 138.69 million. The market for neurotrophic keratitis is defined by a variety of medications created to handle the particular difficulties this illness presents. In all stages of NK, artificial tears are the primary line of treatment. Similar tasks are carried out by a variety of formulations based on polymers without preservatives. Elevated lubrication facilitates epithelialization by decreasing proinflammatory cytokine levels on the eye surface and the shear pressures produced by blinking. To treat the underlying cause of neurotrophic keratitis, nerve growth factor stimulators work to encourage the growth and healing of corneal nerves.
Application (Stage I, Stage II, Stage III)
Neurotrophic keratitis market from the stage II segment was assessed at USD 66.48 million in 2023 and is expected to have a value of USD 499.35 million by 2036, rising at a substantial CAGR of 17.02% over the projected time frame. The goal of stage II therapy is to encourage PED repair and stop a corneal ulcer from forming. Treatment options include amniotic membrane grafting, topical autologous serum application, lubricating ointments, therapeutic soft contact lenses or patching, tarsorrhaphy or botulinum-induced ptosis, and topical recombinant human nerve growth factor therapy. To fight bacterial infections, doctors can give antibiotic eye drops. Although topical corticosteroids may cause stromal melting, they can be used with caution to reduce inflammation.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
Application |
|
North American Market Forecast
The neurotrophic keratitis market in North America is projected to be the largest with the largest revenue of USD 458.34 million by the end of 2036 by growing at a CAGR of 17.16% over the forecast period. The market for neurotrophic keratitis is growing in North America because to the dominance of large players in the region and the increasing number of new product launches. Moreover, congenital conditions, herpes simplex infections, chemical or thermal burns, diabetes, cranial nerve injury, and chronic conditions of the ocular surface are common causes of neurotrophic keratopathy. In 2021, 29.7 million Americans of all ages (8.9% of the US population) had been diagnosed with diabetes, according to the CDC, and by the time they reach their fifth decade of life, about 12% of Americans had tested positive for HSV-2. Effective therapies are in higher need as the prevalence of these causal variables increases and incidences of neurotrophic keratitis rise.
APAC Market Statistics
The Asia Pacific neurotrophic keratitis market is estimated to be the second-largest by developing at a CAGR of 17.65% during the forecast period. The Asia Pacific market is expected to be worth USD 401.59 million by the end of 2036, up from USD 49.87 million in 2023. The focus on early detection and cutting-edge treatment options for eye illnesses is growing in the region's healthcare system. The market is growing as a result of factors like increased healthcare spending, bettering medical infrastructure, and a rise in R&D activity. The need for healthcare is also growing since those over 65 are quickly making up a greater share of the population in Southeast Asia (especially in the more populous countries of Indonesia, Vietnam, Thailand, and the Philippines), China, and India. The percentage of adults in ASEAN countries who are 60 years of age or older was 9.8% in 2017, and according to WHO estimates, that number is projected to increase to 13.7% in 2030 and 20.3% by 2050.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?